New antibody shot could trap nicotine in smokers
NCT ID NCT07215923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ATI-1013 in 15 healthy smokers. The drug is an antibody designed to bind to nicotine in the body. The main goal is to check safety and see how long the drug stays in the system. Participants get one IV dose of the drug or a placebo and are monitored for about 3 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOANGIITIS OBLITERANS (BUERGER'S DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Vince Clinical Research
RECRUITINGOverland Park, Kansas, 66212, United States